NDAs Resubmitted for Alogliptin for Diabetes
Furiex Pharmaceuticals announced its resubmission of two New Drug Applications (NDAs) for alogliptin (Nesina) to the FDA. One NDA is for marketing approval of alogliptin and the second is for the fixed-dose combination therapy of alogliptin + pioglitazone.
Alogliptin is a dipeptidyl peptidase IV or DPP-4 inhibitor being investigated as an adjunct to diet and exercise for the treatment of type 2 diabetes.
For more information call (919) 456-7814 or visit www.furiex.com.